Search Result

Results for "

pancreatic adenocarcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (4) ADC Payload (2) Akt (5) Aminotransferases (Transaminases) (1) Androgen Receptor (6) Apoptosis (38) ATM/ATR (2) Aurora Kinase (3) Autophagy (8) Bacterial (2) Bcl-2 Family (2) Beclin1 (2) Biochemical Assay Reagents (2) c-Met/HGFR (1) c-Myc (3) Cadherin (1) Calcium Channel (4) Casein Kinase (1) Caspase (9) CCR (1) CDK (4) Cholecystokinin Receptor (1) Cholinesterase (ChE) (1) Claudin (3) CTLA-4 (2) Cytochrome P450 (2) Discoidin Domain Receptor (1) DNA/RNA Synthesis (4) Drug Derivative (4) Drug Intermediate (1) Drug Isomer (2) Drug-Linker Conjugates for ADC (2) Early 2 Factor (E2F) (2) Endogenous Metabolite (3) Enolase (1) Environmental Pollutants (1) Epigenetic Reader Domain (6) ERK (7) Eukaryotic Initiation Factor (eIF) (1) FAAH (1) FAK (3) FAP (1) Ferroptosis (3) Fluorescent Dye (2) Fungal (1) GABA Receptor (1) Galectin (1) Glucocorticoid Receptor (1) HDAC (3) Histone Demethylase (1) Histone Methyltransferase (1) HSP (2) IKK (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (2) Interleukin Related (4) Isotope-Labeled Compounds (1) JAK (1) JNK (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) Ligands for E3 Ligase (1) Lipase (1) MAGL (1) MDM-2/p53 (2) MEK (5) MetAP (1) Methionine Adenosyltransferase (MAT) (1) METTL3 (1) Mitochondrial Metabolism (1) MMP (2) MNK (5) Molecular Glues (7) mTOR (1) Mucin (1) MyD88 (1) NAMPT (1) NF-κB (4) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) Orexin Receptor (OX Receptor) (4) Orphan Nuclear Receptor (1) Oxidative Phosphorylation (1) p38 MAPK (2) p97 (1) PARP (3) PD-1/PD-L1 (1) PDGFR (1) PERK (4) Phosphatase (1) Phospholipase (1) PI3K (3) PKA (1) Progesterone Receptor (1) PROTACs (6) Radionuclide-Drug Conjugates (RDCs) (1) Raf (1) Ras (20) Reactive Oxygen Species (ROS) (7) Reference Standards (5) Ribosomal S6 Kinase (RSK) (1) ROCK (2) SHP2 (1) Sirtuin (1) SOS1 (1) SphK (1) STING (2) STK33 (1) Tau Protein (1) Thymidylate Synthase (1) Tim3 (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) Topoisomerase (4) Transmembrane Glycoprotein (4) VEGFR (1) Wnt (3) YTHDF (1) β-catenin (2) γ-secretase (1)
By Research Areas:	Cancer (136) Cardiovascular Disease (2) Endocrinology (6) Infection (3) Inflammation/Immunology (14) Metabolic Disease (6) Neurological Disease (14)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Aptamers (2)

141

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145928

Divarasib 5+ Cited Publications GDC-6036	Ras	Cancer
Divarasib (GDC-6036) is an orally active, selective KRAS ^G12C inhibitor with an IC₅₀ of <0.01 μM. Divarasib covalently binds Cys12 in GDP-bound KRAS ^G12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRAS ^G12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRAS ^G12C-mutated solid tumors .

HY-101194

Tin protoporphyrin IX dichloride 15+ Cited Publications Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX	Reactive Oxygen Species (ROS)	Cancer
Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .

HY-148808

Zelasudil RXC007	ROCK	Cancer
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .

HY-173629

RMC-5127	Ras Apoptosis	Cancer
RMC-5127 is a small molecule inhibitor that binds to GTP-targeted KRAS ^G12V, with oral bioavailability and blood-brain barrier permeability. RMC-5127 inhibits the activities of the RAS and MAPK pathways, suppresses the proliferation of KRAS ^G12V-mutant cancer cells and induces their apoptosis. RMC-5127 can be used for the research of KRAS ^G12V-mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer and intracranial KRAS ^G12V tumors .

HY-135985

DCLK1-IN-1 4 Publications Verification	Fluorescent Dye	Cancer
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC₅₀: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1 ⁺ pancreatic ductal adenocarcinoma (PDAC) .

HY-159127

HRS-4642	Ras MEK PERK Apoptosis	Cancer
HRS-4642 is a high affinity, selective, long-acting, and non-covalent KRAS ^G12D inhibitor with a K_d value of 0.083 nM. HRS-4642 inhibits the binding of KRAS ^G12D to SOS1 or RAF1, thereby blocking the downstream MEK-ERK signaling pathway. HRS-4642 promotes Apoptosis. HRS-4642 alone or combined with Carfilzomib (HY-10455) effectively shapes the tumor microenvironment. HRS-4642 has an anti-cancer effect on pancreatic and colorectal cancers carrying the KRAS ^G12D mutation[1][2][3].

HY-P10944

Unlabeled FXX489 NNS309	FAP	Inflammation/Immunology Cancer
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .

HY-W087027

Maleimide-NOTA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Integrin	Cancer
Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ ⁶⁸Ga]Ac-CG6 formed by the conjugation of ⁶⁸Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .

HY-100498

GSK2256098 5+ Cited Publications	FAK Apoptosis	Cancer
GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

HY-145926

MRTX0902 2 Publications Verification	SOS1 Ras	Neurological Disease Cancer
MRTX0902 is a potent, selective, brain-penetrant, and orally active SOS1 inhibitor with a K_i of 1.9 nM. MRTX0902 disrupts the SOS1:KRASG12C protein-protein interaction (PPI). MRTX0902 can be used in research on pancreatic ductal adenocarcinoma .

HY-70006

Galeterone 3 Publications Verification TOK-001; VN-124-1	Molecular Glues Androgen Receptor MNK Cytochrome P450 Apoptosis	Cancer
Galeterone (TOK-001) is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone also functions as a CYP17 inhibitor (IC₅₀ = 47 nM). Galeterone induces cell apoptosis. Galeterone inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research ^[1][2].

HY-122723

GOT1 inhibitor-1 2 Publications Verification	Reactive Oxygen Species (ROS)	Cancer
GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC₅₀ of 8.2 uM. GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

HY-19808

C-DIM12 2 Publications Verification DIM-C-pPhCl	Nuclear Hormone Receptor 4A/NR4A	Neurological Disease Inflammation/Immunology Cancer
C-DIM12 is a potent, orally active Nurr1 modulator. C-DIM12 inhibits the tumor growth and autophagy, and induces the cell apoptosis. C-DIM12 has anti-inflammatory and neuroprotective effects, and can be used for cancer and neurological disease study .

HY-162567

AP-4-139B	HSP Beclin1 Autophagy	Cancer
AP-4-139B is a blood-brain barrier-permeable HSP70 inhibitor with a IC₅₀ of 180 nM against hHSP70. AP-4-139B binds directly to HSP70 and inhibits its ATPase activity. AP-4-139B promotes Autophagy by increasing the phosphorylation of Beclin-1. AP-4-139B exerts antitumor effects in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma .

HY-100669

Mycro 3 5 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99049

Sotigalimab APX005M; APX005M; EPI-0050	TNF Receptor	Inflammation/Immunology
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .

HY-P991564

Arcotatug IBI-343 antibody; HB37A6; TAK-921 Antibody	ADC Antibody Claudin	Cancer
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .

HY-P99237

Sofituzumab MMUC 1206A	Mucin	Cancer
Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a K_d of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model .

HY-139434

JMJD6-IN-1	Histone Demethylase	Cancer
JMJD6-IN-1 is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC₅₀ values of 19.2 μM and 25.2 μM. JMJD6-IN-1 inhibits JMJD6 demethylase activity. JMJD6-IN-1 can be used for the research of lung adenocarcinoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer, oral squamous cell carcinoma, and glioblastoma .

HY-13495

ML281 2 Publications Verification	STK33 PKA Aurora Kinase Bcl-2 Family Apoptosis	Metabolic Disease Cancer
ML281 is a highly selective inhibitor of serine/threonine kinase 33 (STK33) with an IC₅₀ value of 14 nM. ML281 shows 700-fold selectivity over PKA and 550-fold over AurB. ML281 exerts core mechanism by inhibiting STK33: in small cell lung cancer, ML281 downregulates RPS6/BAD signaling phosphorylation, induces apoptosis, and suppresses proliferation, invasion . ML281 reduces STK33-mediated 4-hydroxyphenylpyruvate dioxygenase (HPD) phosphorylation in tyrosinemia . ML281 is suitable for research on STK33 function, KRAS mutation-related cancers (pancreatic cancer, colon cancer, lung adenocarcinoma, etc.), small cell lung cancer, and tyrosinemia-related damage

HY-120272

SMAP-2 1 Publications Verification DT-1154	Phosphatase	Cancer
SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity .

HY-148409

MMRi62	Ferroptosis Apoptosis Autophagy MDM-2/p53	Cancer
MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12 .

HY-144439

HTS07545	Mitochondrial Metabolism	Cardiovascular Disease Cancer
HTS07545 is a potent sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC₅₀ of 30 nM. HTS07545 reduces the decomposition rate of hydrogen sulfide (H₂S). HTS07545 can be used in the research of heart failure and pancreatic ductal adenocarcinoma.

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-N2512

1-Monomyristin 1 Publications Verification	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal	Infection Cancer
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat FAAH and an IC₅₀ of 32 μM against rat MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-156027

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Neurological Disease Inflammation/Immunology Endocrinology Cancer
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .

HY-178521

BAS00602705	Cadherin	Cancer
BAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC) .

HY-151523

KRas G12R inhibitor 1	Ras	Cancer
KRas G12R inhibitor 1 is a covalent inhibitor targeting the common oncogenic mutant KRas G12R with selectivity for the mutant arginine. KRas G12R inhibitor 1 possesses an α,β-diketoamide and exploits strong nucleophilicity of the mutant cysteine and irreversibly binds in the Switch II region of KRas. KRas G12R inhibitor 1 can be researched for K-Ras (G12R)-driven cancer such as pancreatic ductal adenocarcinoma (PDAC) .

HY-177106

ADT-1004	Drug Intermediate Ras	Cancer
ADT-1004 is an orally active prodrug of ADT-007 (HY-157887). ADT-007 is a reversible, highly potent and selective pan-RAS inhibitor that binds to the nucleotide-free conformation of RAS proteins and blocks their GTP activation, thereby inhibiting the downstream MAPK and AKT signaling pathways. ADT-1004 can be used for the research of pancreatic ductal adenocarcinoma .

HY-161767

JWJ-01-306	Molecular Glues Oxidative Phosphorylation Ras	Cancer
JWJ-01-306 is a CRBN-recruiting ZBTB11 Molecular Glues degrader. JWJ-01-306 degrades ZBTB11 and reprograms cellular metabolism, thereby reducing the level of Oxidative Phosphorylation and the activity of the tricarboxylic acid cycle. JWJ-01-306 enhances the response of organoids to K-Ras inhibition. JWJ-01-306 inhibits the proliferation of pancreatic ductal adenocarcinoma cells and melanoma cells. JWJ-01-306 can be used in studies related to pancreatic ductal adenocarcinoma and melanoma .

HY-175202

CIDD-8633	Discoidin Domain Receptor Apoptosis Caspase Interleukin Related PERK	Cancer
CIDD-8633 is a potent DDR2 inhibitor with an IC₅₀ of 6.105 μM. CIDD-8633 inhibits cell migration and halts the cell cycle and induces apoptosis, significantly suppressing pancreatic ductal adenocarcinoma (PDAC) tumor growth. CIDD-8633 can be used for the study of pancreatic cancer such as PDAC .

HY-165245

SBI-183	Transmembrane Glycoprotein	Cancer
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-145928B

Divarasib adipate 5+ Cited Publications GDC-6036 adipate	Ras	Cancer
Divarasib (GDC-6036) adipate is an orally active, selective KRASG12C inhibitor with an IC50 of <0.01 μM. Divarasib adipate covalently binds Cys12 in GDP-bound KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib adipate induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib adipate can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors .

HY-161346A

(Rac)-EBET-1055	PROTACs Epigenetic Reader Domain	Cancer
(Rac)-EBET-1055 is the racemate of EBET-1055 (HY-161346). EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .

HY-161346

EBET-1055	PROTACs Epigenetic Reader Domain	Cancer
EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures . Pink: BET ligand (HY-161387); Blue: CRBN ligase ligand (HY-14658); Black: linker

HY-15211

MRK 003	γ-secretase Apoptosis	Neurological Disease Cancer
MRK 003 is a potent, selective and orally active γ-secretase inhibitor. MRK 003 reduce brain Aβ production in vivo. MRK 003 induces caspase-dependent apoptosis and inhibits tumor cell proliferation in vivo and in vitro .

HY-153067

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer .

HY-139638

MEK4 inhibitor-1	MEK	Cancer
MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

HY-139639

MEK4 inhibitor-2	MEK	Cancer
MEK4 inhibitor-2 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 83 nM.

HY-N6237

Aspulvinone O	Aminotransferases (Transaminases) Apoptosis	Cancer
Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models .

HY-118054

LRH-1 Inhibitor-3	Orphan Nuclear Receptor	Cancer
LRH-1 Inhibitor-3 is a small molecule that inhibits LRH-1 transcriptional activity, thereby decreasing the expression of target genes associated with cell growth and proliferation. LRH-1 Inhibitor-3 has shown potential in reducing cancer cell proliferation in human pancreatic, colon, and breast adenocarcinoma cell lines. LRH-1 Inhibitor-3 serves as a molecular probe for investigating the role of LRH-1 in various malignancies.

HY-70006A

Galeterone hydrochloride TOK-001 hydrochloride; VN-124-1 hydrochloride	Molecular Glues Androgen Receptor MNK Cytochrome P450 Apoptosis	Cancer
Galeterone (TOK-001) hydrochloride is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone hydrochloride also functions as a CYP17 inhibitor (IC₅₀ = 47 nM). Galeterone hydrochloride induces cell apoptosis. Galeterone hydrochloride inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone hydrochloride can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research ^[1][2].

HY-147838

Nampt-IN-9	NAMPT	Cancer
Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .

HY-155222

TW9	Epigenetic Reader Domain HDAC	Cancer
TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with K_Ds of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC₅₀ of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026) .

HY-175529

KRASG12D-IN-7	Ras ERK Apoptosis	Cancer
KRASG12D-IN-7 is a selective KRAS ^G12D inhibitor. KRASG12D-IN-7 displays strong binding activity for KRAS ^G12D in both its GDP- and GTP- bound states, with K_d value of 1.12 nM and 1.86 nM, respectively. KRASG12D-IN-7 inhibits the proliferation of KRAS ^G12D harboring AsPC-1 cells with an IC₅₀ value of 10 nM and suppresses MAPK signaling. KRASG12D-IN-7 induces G0/G1 phase arrest and apoptosis in AsPC-1 cells, and strongly inhibits their colony formation. KRASG12D-IN-7 can be used for the study of cancers harboring KRAS ^G12D mutation, particularly pancreatic ductal adenocarcinoma (PDAC) .

HY-148260

KRAS G12D inhibitor 16	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

HY-178461

LDHA-IN-10	Lactate Dehydrogenase	Cancer
LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC₅₀ value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .

Cat. No.	Product Name	Target	Research Area

HY-P10944

Unlabeled FXX489 NNS309	FAP	Inflammation/Immunology Cancer
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .

HY-P1676

cyclo(RLsKDK) 2 Publications Verification BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .

HY-P1676A

cyclo(RLsKDK) TFA 2 Publications Verification BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .

HY-P3203

DSTYSLSSTLTLSK	Biochemical Assay Reagents	Inflammation/Immunology
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P11785

Cpe30 MT2	Claudin	Cancer
Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a K_d value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99058

Zolbetuximab 4 Publications Verification IMAB362; Claudiximab; GC-182	Inhibitory Antibodies	Cancer
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99049

Sotigalimab APX005M; APX005M; EPI-0050	TNF Receptor	Inflammation/Immunology
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .

HY-P991564

Arcotatug IBI-343 antibody; HB37A6; TAK-921 Antibody	ADC Antibody Claudin	Cancer
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .

HY-P99237

Sofituzumab MMUC 1206A	Mucin	Cancer
Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a K_d of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

HY-P991481

S-531011	CCR	Inflammation/Immunology Cancer
S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 ⁺regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma .

HY-P99809

Quavonlimab MK-1308	CTLA-4	Cancer
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .

HY-P99537

Ulenistamab PBP1510	Inhibitory Antibodies	Cancer
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research .

HY-P992350

EBC-129 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets CEACAM5 and CEACAM6 glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma .

HY-P991973

HuL001	Enolase	Cancer
HuL001 is a specific monoclonal antibody targeting ENO1. HuL001 remodels the tumor microenvironment by inhibiting cancer-associated fibroblasts, thereby suppressing the progression of multiple myeloma. HuL001 can be used for research on cancers such as colorectal cancer, pancreatic ductal adenocarcinoma, and myeloma .

HY-P992366

HFB200901	Galectin Tim3	Cancer
HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS ^G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 ⁺ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .

HY-P992167

AB011	Claudin	Cancer
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .

HY-P992379

IB001 BAG3-H2L4	Bcl-2 Family	Cancer
IB001 is a humanized anti-BAG3 antibody that inhibits BAG3, with a K_D value of 14.4 nM for human BAG3. IB001 blocks BAG3-dependent monocyte/macrophage activation, interferes with the interaction between BAG3 and IFITM-2, and disrupts tumor microenvironment signaling pathways. IB001 inhibits tumor growth, reduces α-SMA-positive fibroblasts, and blocks BAG3-dependent IL-6 release. IB001 accumulates in a time-dependent manner in pancreatic ductal adenocarcinoma tumors. IB001 can be used for research related to pancreatic ductal adenocarcinoma .

HY-P992464

SHR-A1403 Antibody	ADC Antibody c-Met/HGFR Akt ERK	Cancer
SHR-A1403 Antibody is an anti-c-Met monoclonal antibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma .

HY-P992361

HB0030	Transmembrane Glycoprotein	Cancer
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 ⁺ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .

HY-P991989

MRG004A Antibody	ADC Antibody	Cancer
MRG004A Antibody (HuSC1-39) is a monoclonal antibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer .

HY-P992180

AMB8LK	Ferroptosis	Inflammation/Immunology Cancer
AMB8LK is a human monoclonal antibody targeting H-ferritin, with specificity for tumor-associated heterologous ferritin. AMB8LK specifically recognizes and binds to H-ferritin overexpressed on the surface of tumor cells. AMB8LK can be used in research related to cancer and immune diseases .

HY-P991918

KHK2840 IgG2-AAS	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology Cancer
KHK2840 is a potent CD40 agonist with a K_d value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2512

1-Monomyristin 1 Publications Verification	Infection Structural Classification Serenoa repens Classification of Application Fields Palmae Plants Disease Research Fields Steroids	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat FAAH and an IC₅₀ of 32 μM against rat MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-N3312

Matairesinol	Infection Structural Classification other families Classification of Application Fields Anti-aging Lignans Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Source Classification	p38 MAPK JNK NF-κB
Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer .

HY-N6237

Aspulvinone O	Infection Structural Classification Microorganisms Classification of Application Fields Phenols Polyphenols Disease Research Fields Source Classification	Aminotransferases (Transaminases) Apoptosis
Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models .

HY-113513

5-HEPE	Microorganisms Source Classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

HY-134505

Avicin G	Structural Classification Acacia victoriae Benth. Terpenoids Plants Pentacyclic Triterpenoids Fabaceae Source Classification	Ras Phospholipase ERK Akt
Avicin G is a sphingomyelinase inhibitor and plasma membrane disruptor. Avicin G inhibits the enzymatic activities of neutral sphingomyelinases (SMPD2/3) and acid sphingomyelinase (SMPD1), elevates intracellular sphingomyelin levels, and alters the distribution of sphingomyelin. Avicin G interferes with the lateral segregation of GTP- and GDP-bound H-Ras, inhibits the signal output of oncogenic K-Ras and H-Ras, reduces the phosphorylation of ERK and Akt, increases lysosomal pH, and inhibits the endocytic recycling of epidermal growth factor receptor. Avicin G can be used in research related to pancreatic ductal adenocarcinoma and non-small cell lung cancer .

HY-N14093

Aspulvinone H	Structural Classification Microorganisms Phenols Polyphenols Source Classification	Cholinesterase (ChE) Lipase Reactive Oxygen Species (ROS) Apoptosis Bacterial
Aspulvinone H is an orally active inhibitor of AChE, pancreatic lipase, glutamic-oxaloacetic transaminase 1, and α-glucosidase, with IC₅₀ values of 25.95 μM, 47.06 μM, 5.91/6.91 μM, and 4.6 μM, respectively. It has a K_a of 2.14 μM against GOT1 and a K_i of 6.58 μM against α-glucosidase. Aspulvinone H inhibits cancer cell proliferation, interferes with glutamine metabolism, elevates ROS levels, and induces cell apoptosis and S-phase arrest. Aspulvinone H exhibits antibacterial activity against Staphylococcus aureus. Aspulvinone H inhibits the growth of pancreatic ductal adenocarcinoma xenografts. Aspulvinone H reduces postprandial blood glucose in mice. Aspulvinone H can be used in research related to pancreatic ductal adenocarcinoma, diabetes, and Staphylococcus aureus infection .

HY-N16695

(2S,3S)-Pterosin S 14-O-glucoside	Structural Classification Terpenoids Sesquiterpenes Pteridaceae Plants Pteris multifida Poir. Source Classification	Others
(2S,3S)-Pterosin S 14-O-glucoside is a sesquiterpene glycoside compound that can be isolated from the fern Pteris multifida. (2S,3S)-Pterosin S 14-O-glucoside showed no significant cytotoxicity against A549 (human lung adenocarcinoma), LOVO (colon adenocarcinoma), PANC-1 (human pancreatic cancer), and NCI-H446 (human small cell lung cancer) cell lines (IC₅₀ > 100 μM) .

HY-N13944

Argyrin F	Natural Products Microorganisms Source Classification	Apoptosis
Argyrin F a cyclic peptide with antitumoral activities. Argyrin F inhibits cell proliferation, migration, invasion and colony formation by partial induction of apoptosis and epithelial-mesenchymal transition (EMT). Argyrin F stabilizes p27 ^kip, up-regulated p21 ^waf1/cip1 and depletes COX2. Argyrin F can be used for the study of pancreatic ductal adenocarcinoma (PDAC) .

Cat. No.	Product Name	Chemical Structure

HY-152021S

C18 Ceramide-1-phosphate (d18:1/18:0)-d3

C18 Ceramide-1-phosphate (d18:1/18:0)-d₃ is the deuterium labeled C18 Ceramide-1-phosphate (d18:1/18:0) (HY-160850). C18 Ceramide-1-phosphate (d18:1/18:0) is a specific type of long-chain molecule found in murine skin. C18 Ceramide-1-phosphate (d18:1/18:0) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 μM. C18 Ceramide-1-phosphate (d18:1/18:0)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3)
Application:	IHC-P (1) ICC/IF (1) WB (2) ELISA (1)
Isotype:	IgG (2) IgG2a (1)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83519

	Mucin 4 Antibody (YA3264) Mucin-4; Ascites sialoglycoprotein; ASGP; pancreatic adenocarcinoma mucin; Testis mucin; Tracheobronchial mucin	WB	Human
	Mucin 4 Antibody (YA3264) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Mucin 4.

HY-P83519A

	Mucin 4 Antibody (YA3264)(PBS only) Mucin-4; Ascites sialoglycoprotein; ASGP; pancreatic adenocarcinoma mucin; Testis mucin; Tracheobronchial mucin	WB	Human
	Mucin 4 Antibody (YA3264) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Mucin 4.

HY-P86040

	Mucin 4 Antibody (YA5732) Mucin-4; MUC-4; Ascites sialoglycoprotein; ASGP; pancreatic adenocarcinoma mucin; Testis mucin; Tracheobronchial mucin; [Cleaved into: Mucin-4 alpha chain; Ascites sialoglycoprotein 1; ASGP-1; Mucin-4 beta chain; Ascites sialoglycoprotein 2; ASGP-2; ]	IHC-P, ICC/IF, ELISA	Human
	Mucin 4 Antibody (YA5732) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Mucin 4.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-180200

RNK08954		Alkynes
RNK08954 is an orally active KRAS^G12D inhibitor with a K_d of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRAS^G12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRAS^G12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .

Cat. No.	Product Name		Classification

HY-160045

AP1153 aptamer sodium		Aptamers
AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .

HY-164185

P12FR2 sodium		Aptamers
P12FR2 sodium is an aptamer targeting human pancreatic adenocarcinoma up-regulated factor (PAUF). P12FR2 specifically binds to human PAUF with an estimated apparent KD of 77 nM. P12FR2 inhibits PAUF-induced PANC-1 cell migration and pancreatic cancer xenograft growth.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks